Kvinnelige kjønnshormoner/ Noretisteron

Mansour D. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. J Fam Plann Reprod Health Care. 2012 Jul;38(3):148-9. Epub 2012 Jun 12.

Hale GE, Shufelt CL. Hormone therapy in menopause: An update on cardiovascular disease considerations. Trends in Cardiovasc Med. (25) 2015: 540-549.

Stevenson JC, Panay N, Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety. Maturitas (76 ) 2013: 10-21.

Antikonsepsjonsmidler

Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception. 2006; 74: 359-66.

Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol. 2006; 195: 935-41.

Lello S. Nomegestrol acetate: clinical pharmacology. Drugs. 2010 Mar 26;70(5):541-59. doi: 10.2165/11532130-000000000-00000.

Wright KP, Johnson JV. Evaluation of extended and continuous use oral contraceptives. Ther Clin Risk Manag. 2008;4:905-11

Analoger av gonadotropinfrigjørende hormon

Forlenget QT-tid og venøse tromboser som mulig bivirkning av anti-androgener, utredning fra RELIS 2012